Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.
NYS Entity Status
NYS Filing Date
MAY 16, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - ATTENTIVE THERAPY GROUP INC.
Around the Web
- Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
By Caroline Chen - Tuesday Oct 17, 2017
- Space Visitors Film Fest spotlights UFO films, guests
By fey Peter Hartlaub - Tuesday Oct 17, 2017
The Balboa Theatre in San Francisco blends classic sci-fi movies, documentaries and UFO-centric guest speakers Saturday, Oct. 21, at the Space Visitors Film Fest. Well-known films including “Close Encounters of the Third Kind” and “Plan 9 From Outer Space” will anchor the all-day festival, scheduled to start at 10 a.m. and end some time after midnight. The festival also will feature the 2017 documentaries “The Mothman of Point Pleasant” and “Invasion of Chestnut Ridge,” as well as the documentary “Love & Saucers,” with director Brad Abrahams slated to attend. Guest speakers include Ruben Uriarte, the Mutual UFO Network state director for Northern California.
- FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
By Ben Fidler - Tuesday Aug 29, 2017
The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]
- Cancer drug research moving fast in immunotherapy field
By Michelle Fay Cortez - Tuesday Sep 5, 2017
The last few weeks have been historic in the fight against cancer. Novartis got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on its laurels. Research in the field is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. “I can’t think of any other therapies in oncology that have seen such rapid development,” said Rachel Webster, senior director of oncology at Decision Resources Group, a health care research and consulting firm in London.
- 25 years after Ruby Ridge standoff, radical movement grows
By NICHOLAS K. GERANIOS, Associated Press - Wednesday Aug 30, 2017
SPOKANE, Wash. (AP) — It's been a quarter-century since a standoff in the mountains of northern Idaho left a 14-year-old boy, his mother and a federal agent dead and sparked an expansion of radical right-wing groups in the United States that continues today.The gunfight at Ruby Ridge occurred when agents approached Randy Weaver's property near the Canadian border looking for a place to arrest the military veteran on gun charges. They had been investigating him for possible ties to white supremacist and anti-government groups.Weaver, his daughters and a friend holed up in the family's cabin for 11 days before surrendering on Aug. 31, 1992.
- FDA Panel Votes to Support Leukemia Gene-Therapy Treatment
Thursday Jul 13, 2017
A group of cancer experts voted unanimously to support U.S. regulatory approval for a first-of-its kind gene therapy targeting an aggressive form of leukemia in children and young adults.